ArticleCJC pediatric and congenital heart disease2026
Prognostic Implication of Heart Failure With Reduced and Midrange Ejection Fraction in Adults With Congenital Heart Disease.
Article in CJC pediatric and congenital heart disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: In the acquired heart disease population, heart failure (HF) is broadly classified based on left ventricular (LV) ejection fraction (EF) as HF with reduced EF (HFrEF), HF with midrange EF (HFmrEF), and HF with preserved EF (HFpEF). The prognostic role of this LVEF-based HF classification has not been evaluated in the adult congenital heart disease (CHD) population because of anatomic and physiological heterogeneity within this population. The current study aimed to address this knowledge gap, by assessing the prevalence, predictors (correlates), and prognostic implications of HFrEF in adults with CHD. Methods: This is a retrospective cohort study of adults with CHD and morphologic LV as the systemic ventricle. Patients were classified as HFrEF (LVEF ≤40%), HFmrEF (LVEF 41%-49%), and pEF (LVEF ≥50%). Results: Of 7981 patients, 7203 (90%) had pEF, 451 (6%) had HFmrEF, and 327 (4%) had HFrEF. The correlates of HFrEF were older age, male sex, pacemaker implantation, multiple prior sternotomies, and acquired comorbidities such as hypertension, coronary artery disease, diabetes, and atrial fibrillation. The 15-year mortality risk was 18%, 36%, and 67% in the pEF, HFmrEF, and HFrEF groups, respectively ( Conclusions: Given the elevated risk of mortality in patients with LV systolic dysfunction (both mrEF and rEF) and the emerging data suggesting the efficacy of HF therapy in patients with CHD, there is an urgent need to implement HF therapy in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.